Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer

Journal of Clinical Oncology

Volumn 16, Issue 11, 1998, Pages 3649-3655

  Miller, Denis R ^a   Anderson, Gary T ^a   Stark, James J ^a   Granick, Joel L ^a   Richardson, DeJuran ^a  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CARTILADE; SHARK CARTILAGE EXTRACT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CARTILAGE; CHRONIC DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INFLAMMATORY DISEASE; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SHARK;

EID: 0031765890     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.11.3649     Document Type: Article

References (47)

1. Lerner IJ, Kennedy BJ: The prevalence of questionable methods of cancer treatment in the United States. CA Cancer J Clin 42:181-188, 1992
2. Jacobs JJ: Unproven alternative methods of cancer treatment, in DeVita VT, Hellman S. Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia. PA, Lippincott-Raven, 1997, pp 2993-3001
3. Moertel CG, Ames MM, Kovach JS, et al: A pharmacologic and toxicological study of amygdalin. JAMA 255:591-594, 1978
4. Moertel CG, Fleming TR, Rubins J, et al: A phase II trial of amygdalin (laetrile) in human cancer. N Engl J Med 306:201-206, 1982
5. Prudden J: The clinical acceleration of wound healing with cartilage. Surg Gynecol Obstet 105:283-287, 1965
6. Holt S: Nutriceuticals and angiogenesis. New therapeutic horizons. Alternat Complement Ther 1:243-247, 1995
7. Folkman J, Shing Y: Angiogenesis. J Biol Chem 267:10931-10934, 1992
8. Auerbach W, Auerbach R: Angiogenesis inhibition: A review. Pharmacol Ther 63:265-311, 1994
9. Folkman J, Ingber D: Inhibition of angiogenesis. Semin Cancer Biol 3:89-96, 1992
10. 1 on in vitro angiogenesis. Exp Cell Res 204:356-363, 1993
11. Brem H, Folkman J: Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 141:427-439, 1975
12. Sadove M: Inhibition of mammary carcinoma invasiveness with cartilage-derived inhibitor. Surg Forum 28:499-501, 1977
13. Pauli BU: Regulation of tumor invasion by cartilage-derived anti-invasion factor in vitro. J Natl Cancer Inst 67:65-68, 1981
14. Lee A, Langer R: Shark cartilage contains inhibitors of tumor angiogenesis. Science 221:1185-1187, 1983
15. Takigawa H, Nishida Y, Suzuki F, et al: A clonal human chrondrosarcoma cell line produces an anti-angiogenic antitumor factor. Anticancer Res 10:311-316, 1990
16. Oikawa T, Ashino-Fuse H, Shimamura M, et al: A novel angiogenic inhibitor derived from Japanese shark cartilage (1). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis. Cancer Lett 51:181-186, 1990
17. Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 248:1408-1410, 1990
18. Pepper MS, Ferrara N, Orci L, et al: Chondrocytes inhibit endothelial sprout formation in vitro: Evidence for involvement of a transforming growth factor beta. J Cell Physiol 146:170-179, 1991
19. Gomes EM, Souto PR, Felzenswalb I: Shark cartilage-containing preparation protects cells against hydrogen peroxide-induced damage and mutagenesis. Mutat Res 367:204-208, 1996
20. McGuire TR, Kazakoff PW, Hoie EB, et al: Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium. Pharmacotherapy 16:237-244, 1996
21. Folkman J: Isolation of cartilage factor that inhibits tumor neovascularaization. Science 193:70-71, 1976
22. Atassi G: Investigation of the anti-tumor effect of shark cartilage on human xenografts in nude mice. Institute Jules Bordet. Brussels, Belgium, (unpublished report)
23. Lane IW, Contreras E Jr: High rate of bioactivity (reduction of gross tumor size) observed in advanced cancer patients treated with shark cartilage material. J Naturopath Med 3:45-47, 1992
24. 60 Minutes. CBS, February 28, 1993
25. Milner M: Follow-up of cancer patients using shark cartilage. Alternat Complement Ther 2:99-109, 1996
26. Dye JF, Somers SS, Guillou PJ: Simplified quantitation of cytotoxicity by integration of specific lysis against effector cell concentration at a constant target cell concentration and measuring the area under the curve. J Immunol Methods 138:1-13, 1991
27. Quantikine HS: TNF-Alpha Immunoassay. Minneapolis, MN, R and D Systems 28. TL-2 Immunoassay. Minneapolis, MN, R and D Systems
28. Cella D, Tulsky DS, Gray G, et al: The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
29. Asher B, Vargo E: Possible link between shark cartilage and hepatitis. Ann Intern Med 125:780-781, 1996
30. Dupont E, Alaoui-Jamali M, Wang T, et al: Angiostatic and antitumoral activity of Neovastat®, a molecular fraction derived from shark cartilage, Proc Eighty-eighth Annual Meeting. Am Assoc Cancer Res 38:226, 1997 (abstr No. 1530)
31. Dupont E, Alaoui-Jamali M, Wang T: In vitro and in vivo anti-tumor activity of Neovastat® (AE-941), an angiostatic agent derived from shark cartilage. Presented at International Business Communication Conference on Therapeutic Implications and Mechanisms of Angiogenesis Novel Therapeutic Development. Boston. MA, February 10-11, 1997
32. Thibodeau A, Savard PE, Vincent M, et al: Angioslatic activity of Neovastat® (AE-941) assessed by a semi-quantitative embryonic vascularization test. Presented at International Business Communication Conference on Therapeutic Implications and Mechanisms of Angiogenesis Novel Therapeutic Development, Boston, MA, February 10-11, 1997
33. Dupont E, Riviere M, Latreille J, et al: Neovastat: An inhibitor of angiogenesis with anti-cancer activity. Presented at Am Assoc Cancer Res Special Conference Angiogenesis and Cancer, Orlando FL, January 24-28, 1998
34. Levy T, Kudelka A, Verschraegen CF, et al: A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Proc Am Assoc Cancer Res 37:166, 1996 (abstr 1140)
35. Hollingsworth HC, Merino M, Kohn E, et al: Tumor angiogenesis in advanced-stage ovarian carcinoma. Am J Pathol 147:33-39, 1995
36. Eccles S, Box G, Court W, et al: Control of lymphatic and blood-borne metastasis of a rat breast carcinoma by the matrix metalloproteinase inhibitor, batimastat. Proc Am Assoc Cancer Res 37:73, 1996 (abstr 505)
37. Tulpule A, Snyder JC, Espina BM, et al: A phase I study of Tecogalan, a novel angiogenesis inhibitor in the treatment of AIDS-related Kaposi's sarcoma and solid tumors. Blood 84:248a, 1994 (abstr)
38. Voest EF, Kenyon BM, O'Reilly MS, et al: Inhibition of angiogenesis in vivo by interleukin-12. J Nat Cancer Inst 87:581-584, 1995
39. Fotsis T, Pepper M, Adlercreutz H, et al: Gemstein, a dietary derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 90:2690-2694, 1993
40. Messina J, Persley V, Setchell KDR, et al: Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr Cancer 21:113-131, 1994
41. Lane IW: Dr Lane's shark cartilage message forum. Note to those interested in the Denver study. http://www.drlane.com. June 14, 1997
42. Lane IW: Untitled. Dr Lane's Letter. Volume IV, Number 2, 1997
43. Simone C: Results of therapy with shark cartilage in advanced cancer, http://www.drsimone.com/spec/sharks, March 25, 1998
44. Oncology Drug Advisory Committee: Review of Gemcitabine. Rockville, MD, Food and Drug Administration, June 24, 1995
45. Loprinzi CL, Goldberg GM, Su JQ, et al: Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 12:1126-1129, 1994
46. Loprinzi CL, Kuross SA, O'Fallon JR, et al: Randomized placebo-controlled evaluation of hydrazine sulfate in patients with a advanced colorectal cancer. J Clin Oncol 12:1121-1125, 1994
47. Arnst C: Starving tumors to death. Business Week. April 27, 1998, 65-66